Emir Baki Denkbas

Prof. Dr. Emir Baki Denkbas


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
TVTayfun Vural
Tayfun Vural
YYYesim Tugce Yaman
Yesim Tugce Yaman
SÖSerhat Öztürk
Serhat Öztürk
SASerdar Abaci
Serdar Abaci
EDEmir Baki Denkbas
Emir Baki Denkbas

1 February 2014 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
NÇNazlı Çalışkan
Nazlı Çalışkan
CBCem Bayram
Cem Bayram
EEEbru Erdal
Ebru Erdal
ZKZeynep Karahaliloğlu
Zeynep Karahaliloğlu
EDEmir Baki Denkbas
Emir Baki Denkbas

1 September 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
EÇEkin Çelik
Ekin Çelik
CBCem Bayram
Cem Bayram
RARümeysa Akçapınar
Rümeysa Akçapınar
MTMustafa Türk
Mustafa Türk
EDEmir Baki Denkbas
Emir Baki Denkbas

24 May 2006 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
EÖEylem Öztürk
Eylem Öztürk
CACanan Ağalar
Canan Ağalar
KKKaan Keçeci
Kaan Keçeci
EDEmir Baki Denkbas
Emir Baki Denkbas

25 January 2010 in Journal of Bioactive and Compatible Polymers
Verified
Journal Article
Closed access
DKDoğa Kavaz
Doğa Kavaz
SOSedat Odabaş
Sedat Odabaş
EGEylem Guven
Eylem Guven
MDMurat Demirbilek
Murat Demirbilek
EDEmir Baki Denkbas
Emir Baki Denkbas
Iron oxide (Fe3O4) containing magnetic chitosan nanoparticles were prepared with Concanavalin-A and Bleomycin as multifunctional nanocarriers for the targeted cancer therapy by co-precipitation techniques. The chemical structures of nanoparticles were analyzed by FTIR and the magnetic properties of the nanoparticles were evaluated by electron spin resonance technique and vibrational scanning mangnetometer measurements. The in vitro release profiles of Bleomycin were investigated and chitosan nanoparticles characteristics were optimized for subsequent in vivo applications. The magnetic chitosan nanoparticles are biocompatible-based MTT assays. The therapeutic potential of these nanoparticles are being investigated for in vivo applications.

8 May 2019 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
EYEda Yalcin
Eda Yalcin
GKGoknur Kara
Goknur Kara
EÇEkin Çelik
Ekin Çelik
FPFerda Alpaslan Pinarli
Ferda Alpaslan Pinarli
GSGuleser Saylam
Guleser Saylam
EDEmir Baki Denkbas
Emir Baki Denkbas
Small interfering RNA (siRNA)-based gene silencing strategy has high potential on suppressing specific molecular targets, involved in cancer progression. However, the lack of an effective nanocarrier system that safely delivers siRNA to its target still limits the clinical applications of siRNA. This study aimed to develop albumin-sericin nanoparticles (Alb-Ser NPs) as a novel siRNA delivery system for laryngeal cancer treatment. Nanoparticle formulations composed of albumin and sericin at different ratios (1:1, 2:1, 1:2 w/w) were synthesized by desolvation method. The nanoparticles were modified with poly-L-lysine (PLL) for siRNA binding and decorated with hyaluronic acid (HA) to target laryngeal cancer cell line, Hep-2. HA/PLL/Alb-Ser NPs were individually loaded with siRNAs for casein kinase 2 (CK2), Absent, Small, or Homeotic-Like (ASH2L), and Cyclin D1 genes, which are overexpressed in Hep-2 cells. Downregulation of genes was confirmed by real-time PCR (RT-PCR). Size, morphological, and thermogravimetric characterizations revealed that Alb-Ser NPs having 2:1 (w/w) ratio are the most optimized formulation. Between 36.8 and 61.3% of siRNA entrapment efficiencies were achieved. HA/PLL-siRNA/Alb-Ser (2:1) NPs-mediated gene silencing resulted in a significant inhibition of cell growth and induction of apoptosis in cells. Our findings showed that HA/PLL/Alb-Ser (2:1) NPs were promising as a siRNA carrier.